Neuropeptide Y and Markers of Osteoblast Activity in Dialysis Patients: A Cross-Sectional Study

American Journal of Kidney Diseases

Volumn 50, Issue 6, 2007, Pages 1001-1008

  Panuccio, Vincenzo ^a   Cutrupi, Sebastiano ^a   Pizzini, Patrizia ^a   Mallamaci, Francesca ^a   Tripepi, Giovanni ^a   Zoccali, Carmine ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Alkaline phosphatase; bone alkaline phosphatase isoenzyme; low bone turnover; neuropeptide Y; osteoblast activity

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIHYPERTENSIVE AGENT; BIOCHEMICAL MARKER; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; ERYTHROPOIETIN; NEUROPEPTIDE Y;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OSTEOBLAST; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PLASMA; TREATMENT OUTCOME;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEUROPEPTIDE Y; OSTEOBLASTS; PERITONEAL DIALYSIS; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 36248963591     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.09.001     Document Type: Article

References (18)

1. Sherrard D.J., Hercz G., Pei Y., et al. The spectrum of bone disease in end-stage renal failure-An evolving disorder. Kidney Int 43 (1993) 436-442
2. Malluche H.H., and Faugere M.C. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 42 (1992) S62-S67
3. Navarro J.F., Mora C., Jimenez A., Torres A., Macia M., and Garcia J. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis 34 (1999) 43-48
4. Brancaccio D., and Zoccali C. Continuous challenge of cardiovascular and bone and bone disease in uremic patients: Clinical consequences of hyperphosphatemia and advanced therapeutic approach. J Nephrol 19 (2006) 12-20
5. Hernandez J.D., Wesseling K., and Salusky I.B. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodistrophy. Semin Dial 18 (2005) 290-295
6. Jehle P.M., Ostertag A., Schulten K., Schulz W., Jehle D.R., and Stracke S. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int 57 (2000) 423-436
7. Panuccio V., Mallamaci F., Tripepi G., et al. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis 40 (2002) 810-815
8. Caro J.F., Besarab A., Burke J.F., and Glennon J.A. A possible role for propranolol in the treatment of renal osteodystrophy. Lancet 2 (1978) 451-454
9. Hruska K.A., and Teitelbaum S.L. Renal osteodystrophy. N Engl J Med 20 (1995) 166-174
10. Ducy P., Amling M., Takeda S., et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100 (2000) 197-207
11. Baldock P.A., Sainsbury A., Couzens M., et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109 (2002) 915-921
12. Baldock P.A., Allison S., McDonald M.M., et al. Hypothalamic regulation of cortical bone mass: Opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 21 (2006) 1600-1607
13. Stridsberg M., and Lundqvist G. Radioimmunoassay of neuropeptide Y (NPY) in biological fluids. Circulating NPY levels depend on renal function. Clin Chim Acta 185 (1989) 61-71
14. Coen G., Ballanti P., Bonucci E., et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 13 (1998) 2294-2302
15. Practical Statistics for Medical Research. ed 1 (1991), Chapman & Hall, London, UK 303
16. Baldock P.A., Sainsbury A., Couzens M., et al. Neuropeptide Y, tyrosine hydrolase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J Auton Nerv Syst 25 (1988) 119-125
17. Kalra S.P., and Kalra P.S. NPY-Endearing journey in search of neurochemical on/off switch for appetite, sex and reproduction. Peptides 22 (2001) 309-315
18. Baldock P.A., Sainsbury A., Allison S., et al. Hypothalamic control of bone formation: Distinct actions of leptin and y2 receptor pathways. J Bone Miner Res 20 (2005) 1851-1857